Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 587.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 318,875 shares of the company’s stock after purchasing an additional 272,520 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Dr. Reddy’s Laboratories were worth $5,035,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. EverSource Wealth Advisors LLC increased its position in Dr. Reddy’s Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock valued at $29,000 after acquiring an additional 1,507 shares during the period. POM Investment Strategies LLC raised its stake in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after purchasing an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after purchasing an additional 2,093 shares during the period. Sierra Ocean LLC purchased a new position in Dr. Reddy’s Laboratories in the 4th quarter valued at $43,000. Finally, Allworth Financial LP increased its stake in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after buying an additional 2,230 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Stock Up 1.8 %

Dr. Reddy’s Laboratories stock opened at $12.59 on Tuesday. The stock’s 50 day moving average price is $13.31 and its 200 day moving average price is $14.47. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.28 and a 1-year high of $16.89. The company has a market cap of $10.51 billion, a PE ratio of 20.04 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, sell-side analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.